Wilmington, DE -- (SBWIRE) -- 12/19/2013 -- Equity Profile Report expands its NASDAQ Active Stock Watch List adding Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) and Altera Corp. (NASDAQ:ALTR).
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) a biopharmaceutical company that focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States is currently up (+4.01%) on 3,214,299 shares traded after Keryx Biopharmaceuticals Announced Issuance of U.S. Patent for Zerenex Covering Orally Administrable Forms of Ferric Citrate. Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) is currently up (+422.4%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)
Altera Corp. (NASDAQ:ALTR) a semiconductor company that designs, manufactures, and markets programmable logic devices, HardCopy application-specific integrated circuit devices, pre-defined design building blocks, and proprietary development software is currently down (-0.38%) on 1,609,956 shares traded after Altera Received Huawei 2013 Excellent Core Partner Award. Altera Corp. (NASDAQ:ALTR) is currently down (-19.88%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Altera Corp. (NASDAQ:ALTR)
Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.Equityprofilereport.com
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.
Equity Profile Report